Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

ABSTRACT:

Background

The ERSPC (European Randomized Study of Screening for Prostate Cancer) found that screening reduced prostate cancer mortality, but the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found no reduction.

Objective

To evaluate whether effects of screening on prostate cancer mortality relative to no screening differed between the ERSPC and PLCO.

Design

Cox regression of prostate cancer death in each trial group, adjusted for age and trial. Extended analyses accounted for increased incidence due to screening and diagnostic work-up in each group via mean lead times (MLTs), which were estimated empirically and using analytic or microsimulation models.

Setting

Randomized controlled trials in Europe and the United States.

Participant

SUBMITTER: Tsodikov A 

PROVIDER: S-EPMC5734053 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature